Literature DB >> 28219888

CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice.

Yi Zhou1,2, Huimei Chen2,3, Li Liu2,4, Xueqing Yu5, Galina K Sukhova2, Min Yang6, Lijun Zhang2, Vasileios C Kyttaris7, George C Tsokos7, Isaac E Stillman8, Takaharu Ichimura2, Joseph V Bonventre2, Peter Libby2, Guo-Ping Shi9.   

Abstract

CD74 mediates MHC class-II antigenic peptide loading and presentation and plays an important role in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus. C57BL/6 Faslpr mice that develop spontaneous lupus-like autoimmunity and pathology showed elevated CD74 expression in the inflammatory cell infiltrates and the adjacent tubular epithelial cells (TECs) in kidneys affected by lupus nephritis but negligible levels in kidneys from age-matched wild-type mice. The inflammatory cytokine IFN-γ or IL-6 induced CD74 expression in kidney TECs in vitro. The presence of kidney TECs from Faslpr mice, rather than from wild-type mice, produced significantly stronger histones, dsDNA, and ribonucleoprotein-Smith Ag complex-induced CD4+ T cell activation. Splenocytes from CD74-deficient FaslprCd74-/- mice had muted responses in a MLR and to the autoantigen histones. Compared with FaslprCd74+/+ mice, FaslprCd74-/- mice had reduced kidney and spleen sizes, splenic activated T cells and B cells, serum IgG and autoantibodies, urine albumin/creatinine ratio, kidney Periodic acid-Schiff score, IgG and C3 deposition, and serum IL-6 and IL-17A levels, but serum IL-2 and TGF-β levels were increased. Study of chronic graft-versus-host C57BL/6 mice that received donor splenocytes from B6.C-H2bm12 /KhEg mice and those that received syngeneic donor splenocytes yielded similar observations. CD74 deficiency reduced lupus-like autoimmunity and kidney pathology in chronic graft-versus-host mice. This investigation establishes the direct participation of CD74 in autoimmunity and highlights a potential role for CD74 in kidney TECs, together with professional APCs in systemic lupus erythematosus.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28219888      PMCID: PMC5360510          DOI: 10.4049/jimmunol.1600028

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  89 in total

1.  Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice.

Authors:  Déborah Braun; Pedro Geraldes; Jocelyne Demengeot
Journal:  J Autoimmun       Date:  2003-02       Impact factor: 7.094

2.  Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5.

Authors:  Xiang-Ping Yang; Kamran Ghoreschi; Scott M Steward-Tharp; Jaime Rodriguez-Canales; Jinfang Zhu; John R Grainger; Kiyoshi Hirahara; Hong-Wei Sun; Lai Wei; Golnaz Vahedi; Yuka Kanno; John J O'Shea; Arian Laurence
Journal:  Nat Immunol       Date:  2011-01-30       Impact factor: 25.606

3.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

Review 4.  CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease.

Authors:  Federica Borghese; Felix I L Clanchy
Journal:  Expert Opin Ther Targets       Date:  2011-01-06       Impact factor: 6.902

Review 5.  Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture.

Authors:  F Castellino; G Zhong; R N Germain
Journal:  Hum Immunol       Date:  1997-05       Impact factor: 2.850

6.  Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus.

Authors:  E E Solomou; Y T Juang; M F Gourley; G M Kammer; G C Tsokos
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

7.  Cytokine production, serum levels and disease activity in systemic lupus erythematosus.

Authors:  G Gröndal; I Gunnarsson; J Rönnelid; S Rogberg; L Klareskog; I Lundberg
Journal:  Clin Exp Rheumatol       Date:  2000 Sep-Oct       Impact factor: 4.473

8.  The role of IL-23/IL-17 axis in lupus nephritis.

Authors:  Zheng Zhang; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2009-08-05       Impact factor: 5.422

9.  Co-Positivity for Anti-dsDNA, -Nucleosome and -Histone Antibodies in Lupus Nephritis Is Indicative of High Serum Levels and Severe Nephropathy.

Authors:  Jinfeng Yang; Zhaozhen Xu; Manshu Sui; Jihua Han; Lijie Sun; Xiuzhi Jia; Haiyu Zhang; Changsong Han; Xiaoming Jin; Fei Gao; Yanhong Liu; Yang Li; Jianbin Cao; Hong Ling; Fengmin Zhang; Huan Ren
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

Review 10.  Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects.

Authors:  Emanuele Cozzani; Massimo Drosera; Giulia Gasparini; Aurora Parodi
Journal:  Autoimmune Dis       Date:  2014-02-06
View more
  6 in total

Review 1.  T cell help in the autoreactive germinal center.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  Scand J Immunol       Date:  2022-05-31       Impact factor: 3.889

Review 2.  Macrophage Migration Inhibitory Factor (MIF) as a Stress Molecule in Renal Inflammation.

Authors:  Yao-Zhong Kong; Qiyan Chen; Hui-Yao Lan
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

3.  Lupus Susceptibility Loci Predispose Mice to Clonal Lymphocytic Responses and Myeloid Expansion.

Authors:  Elliot H Akama-Garren; Michael C Carroll
Journal:  J Immunol       Date:  2022-04-27       Impact factor: 5.426

4.  Proteomic Analysis Revealed the Characteristics of Key Proteins Involved in the Regulation of Inflammatory Response, Leukocyte Transendothelial Migration, Phagocytosis, and Immune Process during Early Lung Blast Injury.

Authors:  Yunen Liu; Changci Tong; Peifang Cong; Ying Liu; Xiuyun Shi; Lin Shi; Shun Mao; Yan Zhao; Hongxu Jin; Mingxiao Hou
Journal:  Oxid Med Cell Longev       Date:  2021-04-27       Impact factor: 6.543

Review 5.  Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics.

Authors:  Ryan Brown; Sridesh Nath; Alnardo Lora; Ghassan Samaha; Ziyad Elgamal; Ryan Kaiser; Clifford Taggart; Sinéad Weldon; Patrick Geraghty
Journal:  Respir Res       Date:  2020-05-12

Review 6.  Role of MIF Cytokine/CD74 Receptor Pathway in Protecting Against Injury and Promoting Repair.

Authors:  Laura Farr; Swagata Ghosh; Shannon Moonah
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.